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Abstract 
The goal of this in vitro study was to examine the effect of the alpha-2 adrenoceptor agonist 
dexmedetomidine on phenylephrine (alpha-1 adrenoceptor agonist)-induced contraction in 
isolated rat aortae and to elucidate the associated cellular mechanisms, with a particular focus on 
alpha-1 adrenoceptor antagonism. Dexmedetomidine dose-response curves were generated in 
isolated endothelium-intact and endothelium-denuded rat aortae precontracted with 
phenylephrine or 5-hydroxytryptamine. Endothelium-denuded aortic rings were pretreated with 
either dexmedetomidine or the reversible alpha-1 adrenoceptor antagonist phentolamine, 
followed by post-treatment with the irreversible alpha-1 adrenoceptor blocker 
phenoxybenzamine. Control rings were treated with phenoxybenzamine alone. All rings were 
repeatedly washed with Krebs solution to remove all pretreatment drugs, including 
phenoxybenzamine, phentolamine and dexmedetomidine. Phenylephrine dose-response curves 
were then generated. The effect of rauwolscine on the dexmedetomidine-mediated change in 
phenylephrine-induced endothelial nitric oxide synthase (eNOS) phosphorylation in human 
umbilical vein endothelial cells was examined using western blotting. The magnitude of the 
dexmedetomidine-mediated inhibition of phenylephrine-induced contraction was higher in 
endothelium-intact aortae than in endothelium-denuded aortae or endothelium-intact aortae 
treated with Nω-nitro-L-arginine methyl ester. However, dexmedetomidine did not significantly 
alter 5-hydroxytryptamine-induced contraction. In further experiments, prazosin attenuated 
dexmedetomidine-induced contraction. Additionally, pretreatment with either dexmedetomidine 
plus phenoxybenzamine or phentolamine plus phenoxybenzamine produced greater 
phenylephrine-induced contraction than phenoxybenzamine alone, suggesting that 
dexmedetomidine protects aortae from the alpha-1 adrenoceptor blockade induced by 
phenoxybenzamine. Rauwolscine attenuated the dexmedetomidine-mediated enhancement of 
phenylephrine-induced eNOS phosphorylation. Taken together, these results suggest that 
dexmedetomidine attenuates phenylephrine-induced contractions via alpha-1 adrenoceptor 
blockade and endothelial nitric oxide release in the isolated rat aorta. 
Key words: dexmedetomidine, phenylephrine, alpha-2 adrenoceptor agonist, alpha-1 adrenoceptor, 
contraction, aorta, phenoxybenzamine, phentolamine, nitric oxide. 
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Introduction 
The highly selective alpha-2 adrenoceptor 
agonist dexmedetomidine is widely used for sedation 
in perioperative periods [1,2]. Intravenous 
administration of dexmedetomidine produces 
transient hypertension followed by hypotension, due 
to alpha-2 adrenoceptor-mediated vasoconstriction 
and a central sympatholytic effect, respectively [1-3]. 
The hypotension caused by dexmedetomidine 
infusion during various procedures requires a large 
amount of phenylephrine [4-6]. Furthermore, 
dexmedetomidine attenuates the contraction induced 
by the alpha-1 adrenoceptor agonist phenylephrine in 
isolated vessels [7,8]. In addition, it has been reported 
that dexmedetomidine shows low affinity for the 
alpha-1 adrenoceptor [9,10]. These previous reports 
suggest that high doses of dexmedetomidine induce 
competitive inhibition at the alpha-1 adrenoceptor via 
the intrinsic low affinity of dexmedetomidine for the 
alpha-1 adrenoceptor [7-10]. The vasoconstriction 
induced by dexmedetomidine is attenuated by 
endothelial nitric oxide in isolated endothelium-intact 
rat aortae [11]. However, the detailed cellular 
mechanism responsible for the dexmedetomidine- 
mediated inhibition of alpha-1 adrenoceptor-induced 
contraction remains unknown. Therefore, the goal of 
this in vitro study was to examine the effect of 
dexmedetomidine on phenylephrine-induced 
contraction in isolated rat aorta and to elucidate the 
associated cellular mechanism, with a particular focus 
on the antagonistic effects on the alpha-1 
adrenoceptor. We tested the hypothesis that 
dexmedetomidine attenuates phenylephrine-induced 
contraction via both inhibition of the alpha-1 
adrenoceptor and activation of endothelial nitric 
oxide release.  
Materials and Methods  
All experimental procedures and protocols were 
approved by the Institutional Animal Care and Use 
Committee of Gyeongsang National University and 
were performed in accordance with the Guide for the 
Care and Use of Laboratory Animals as described 
previously [12].  
Preparation of aortic rings for tension 
measurements 
Aortic rings were prepared for tension 
measurements as described previously [12-14]. Male 
Sprague-Dawley rats weighing 250–300 g were 
anesthetized via intramuscular injection of Zoletil 50 
(15 mg/kg, Virbac Laboratories, Carros, France). The 
descending thoracic aorta was then dissected free. The 
surrounding connective tissue and fat were removed 
under a microscope, and the vessel was bathed in 
Krebs solution with the following composition (mM): 
118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.4 CaCl2, 
25 NaHCO3, and 11 glucose. The aorta was then cut 
into 2.5-mm rings, which were suspended on Grass 
isometric transducers (FT-03, Grass Instrument, 
Quincy, MA, USA) under 3.0-g resting tension in a 
10-mL Krebs bath at 37°C and continuously aerated 
with 95% O2 and 5% CO2 to maintain pH values 
within 7.35–7.45. The rings were equilibrated at a 
resting tension of 3.0 g for 120 min, during which the 
bathing solution was changed every 40 min. Care was 
taken not to damage the endothelium. In some aortic 
rings, the endothelium was intentionally removed by 
inserting a 25-gauge needle tip into the lumen of the 
ring and gently rolling the ring for a few seconds. 
Once the phenylephrine (10−7 M)-induced contraction 
had stabilized, acetylcholine (10−5 M) was added to 
assess endothelial integrity. Endothelial integrity was 
confirmed by the observation of more than 75% 
relaxation induced by acetylcholine. Once the 
phenylephrine (10-8 M)-induced contraction was 
sustained in the endothelium-denuded rat aorta, 
acetylcholine was added to assess endothelial 
denudation; aortic rings showing lees than 20% 
relaxation induced by acetylcholine were regarded as 
endothelium-denuded aortic rings in the current 
experiment. The rings were then rinsed with fresh 
Krebs solution to restore the resting tension. Next, the 
contraction induced by isotonic 60 mM KCl was 
measured, and the magnitude of isotonic 60 mM 
KCl-induced contraction was used as the reference 
value (100%) for concentration-response curves 
induced by phenylephrine [13]. After washing out the 
KCl from the organ bath with fresh Krebs solution 
and reaching the baseline resting tension, the main 
experiments were performed as described in the 
experimental protocols.  
Experimental protocols 
We investigated the dexmedetomidine 
concentration (10-9 to 10-6 M)-response curves in 
isolated endothelium-intact aortae that were either 
precontracted with phenylephrine (10-6 M) or 
pretreated with the nitric oxide synthase inhibitor 
Nω-nitro-L-arginine methyl ester (L-NAME: 10−4 M) 
and precontracted with phenylephrine (10-6 M) as 
well as endothelium-denuded aortae pretreated with 
L-NAME (10−4 M) and precontracted with 
phenylephrine (10-7 M). We regarded isolated rat 
aortae showing less than 20% acetylcholine-induced 
relaxation as endothelium-denuded aortae in the 
current experiment, and endothelial nitric oxide 
attenuates dexmedetomidine-induced contraction 
[11]. As the residual endothelium of the endothelium- 
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denuded aorta may affect dexmedetomidine 
concentration-response curves, endothelium- 
denuded aortae were pretreated with 10−4 M L-NAME 
for 15 min before the addition of phenylephrine. After 
phenylephrine had produced a stable and sustained 
contraction in the isolated rat aorta, dexmedetomidine 
was cumulatively added to generate dexmedeto-
midine concentration-response curves.  
An alpha-1 adrenoceptor protection experiment 
was performed to determine whether the 
dexmedetomidine-mediated inhibition of 
vasoconstriction induced by the alpha-1 adrenoceptor 
agonist phenylephrine involves alpha-1 adrenoceptor 
blockade [15,16]. Endothelium-denuded rat aortae 
were pretreated with either dexmedetomidine (3 × 
10-7, or 10-6 M) or the reversible alpha-1 adrenoceptor 
antagonist phentolamine (10-6 M) for 20 min, followed 
by post-treatment with the irreversible alpha-1 
adrenoceptor antagonist phenoxybenzamine (5 × 10-8 
M) for another 20 min. Control rings were treated 
with phenoxybenzamine (5 × 10-8 M) alone for 20 min. 
All rings were repeatedly washed with fresh Krebs 
solution every 5 min for 60 min to remove all of the 
pretreatment drugs, including phenoxybenzamine, 
dexmedetomidine and phentolamine, and to restore 
the baseline resting tension. Then, phenylephrine 
concentration (10-9 to 10-5 M)-response curves were 
generated in the endothelium-denuded washed aorta 
pretreated with L-NAME (10−4 M).  
We investigated the effect of the cumulative 
addition of dexmedetomidine on the contraction 
induced by phenylephrine (10-7 M) or 
5-hydroxytryptamine (3 × 10-6 M) in an isolated 
L-NAME (10−4 M)-pretreated endothelium-denuded 
rat aorta to determine whether the inhibitory effect of 
dexmedetomidine on phenylephrine-induced 
contraction is specifically associated with inhibitory 
effects on the alpha-1 adrenoceptor. After 
phenylephrine or 5-hydroxytryptamine had produced 
a sustained and stable contraction in the 
endothelium-denuded rat aorta pretreated with 
L-NAME (10-4 M), dexmedetomidine (10-9 to 10-6 M) 
was cumulatively added to generate dexmedeto-
midine concentration-response curves. In addition, 
we generated prazosin concentration (10-10 to 3 × 10-9 
M)-response curves in endothelium-denuded aortae 
that were pretreated with L-NAME (10-4 M) and 
precontracted with dexmedetomidine (10-6 M).  
Cell culture  
Human umbilical vein endothelial cells 
(HUVECs; EA.hy926 cells, American Type Culture 
Collection, Manassas, VA, USA) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 2 
mmol/L L-glutamine, 100 IU/mL penicillin, and 10 
μg/mL streptomycin as described previously [12]. 
The cells were cultured in 100-mm dishes and grown 
in a humidified 5% CO2 incubator. HUVECs were 
plated at a density of 107 cells per 100-mm dish. The 
cells were used between passage number 7 and 
passage number 10. 
Western blot analysis  
Western blot analysis was performed as 
previously described [12]. Briefly, cells were lysed in 
PRO-PREP protein extract solution to isolate the total 
cell extract. After the extract was centrifuged at 13,000 
rpm for 20 min at 4°C, the protein concentration was 
determined via the Bradford method. Samples 
containing 30 µg of protein were subjected to 10% 
sodium dodecyl sulfate (SDS)–polyacrylamide gel 
electrophoresis. The separated proteins were then 
transferred to polyvinylidene difluoride membranes 
using the SD Semi-dry Transfer Cell® system 
(Bio-Rad, Hercules, CA, USA). These membranes 
were incubated with primary antibodies 
(anti-endothelial nitric oxide synthase [eNOS] and 
anti-phospho-eNOS at Ser1177 antibodies; Cell 
Signaling Technology, Beverly, MA, USA) at a 1:500 
dilution (4 μg/mL) in 5% skim milk in Tris-buffered 
saline with Tween 20 overnight at 4°C, and bound 
antibody was detected with horseradish 
peroxidase-conjugated anti-rabbit IgG. The 
membranes were washed and then developed using 
the Luminol Reagent system (Animal Genetics, 
Suwon, Korea).  
Materials  
Phenylephrine, prazosin, phenoxybenzamine, 
phentolamine, 5-hydroxytryptamine, L-NAME and 
acetylcholine were obtained from Sigma-Aldrich (St. 
Louis, Missouri, USA). Dexmedetomidine was 
donated from Orion Pharma (Turku, Finland). 
DMEM, FBS, penicillin and streptomycin were 
obtained from Gibco BRL (Rockville, MD, USA). 
Phentolamine and phenoxybenzamine were dissolved 
in ethanol. Unless otherwise stated, we dissolved and 
diluted all other drugs in distilled water.  
Data analysis  
 Dexmedetomidine concentration-response 
curves are expressed as the percentage of maximal 
contraction induced by phenylephrine or 
5-hydroxytryptamine. Concentration-response curves 
induced by phenylephrine are expressed as the 
percentage of maximal contraction induced by 
isotonic 60 mM KCl. The effects of phenylephrine, 
5-hydroxytyptamine and endothelial denudation on 
the dexmedetomidine concentration-response curves 
and the effects of various drugs on the phenylephrine 
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dose-response curves were analyzed through 
two-way repeated measurement analysis of variance 
(ANOVA) followed by Bonferroni’s post-test. 
Prazosin concentration-response curves were 
analyzed using repeated measures ANOVA followed 
by Bonferroni’s post-test. The effects of 
dexmedetomidine alone or combined treatment with 
rauwolscine and dexmedetomidine on 
phenylephrine-induced eNOS phosphorylation in 
HUVECs were analyzed using one-way ANOVA 
followed by Bonferroni’s post-test. Data are expressed 
as the mean ± SD. N indicates the number of rats from 
which descending thoracic aortic rings were derived 
or the number of isolated rat thoracic aortic rings. P 
values less than 0.05 were considered statistically 
significant.  
Results  
 A high dose (10-7 to 10-6 M) of dexmedetomidine 
attenuated phenylephrine-induced contraction (Fig. 1; 
P < 0.05 versus 10-9 M dexmedetomidine) in 
endothelium-intact aortae, endothelium-intact aortae 
pretreated with L-NAME (10-4 M) and 
endothelium-denuded aortae pretreated with 
L-NAME (10-4 M). However, the dexmedetomidine 
(10-7 to 10-6 M)-mediated attenuation of 
phenylephrine-induced contraction was greater in 
endothelium-intact aortae than in endothelium-intact 
or endothelium-denuded aortae pretreated with 
L-NAME (Fig. 1; P < 0.05). Combined treatment with 
either dexmedetomidine (3 × 10-7 or 10-6 M) and 
phenoxybenzamine (5 × 10-8 M) or phentolamine (10-6 
M) and phenoxybenzamine (5 × 10-8 M) enhanced 
phenylephrine-induced contraction compared with 
phenoxybenzamine alone (5 × 10-8 M) (Fig. 2; P < 0.001 
at 10-7 to 10-5 M phenylephrine). In addition, 
combined treatment with phentolamine and 
phenoxybenzamine enhanced phenylephrine-induced 
contraction compared with dexmedetomidine (10-6 M) 
and phenoxybenzamine combined treatment (Fig. 2; P 
< 0.001 at 10-8 and 3 × 10-8 M phenylephrine). 
Combined treatment with high concentrations of 
dexmedetomidine (10-6 M) and phenoxybenzamine 
enhanced phenylephrine-induced contraction 
compared with combined treatment with low 
concentrations of dexmedetomidine (3 × 10-7 M) and 
phenoxybenzamine (Fig. 2; P < 0.05 at 3 × 10-8 to 3 × 
10-7 M phenylephrine). Dexmedetomidine had no 
effect on 5-hydroxytryptamine-induced contraction in 
isolated L-NAME-pretreated endothelium-denuded 
aortae, whereas a high dose (10-7 to 10-6 M) of 
dexmedetomidine attenuated phenylephrine-induced 
contraction (Fig. 3A; P < 0.001 versus 
5-hydroxytryptamine). Prazosin (3 × 10-9 M) 
attenuated dexmedetomidine-induced contraction 
(Fig. 3B; P < 0.001 versus 10-6 M dexmedetomidine). 
Phenylephrine (10-8 M) induced eNOS 
phosphorylation in HUVECs (Fig. 4; P < 0.001 versus 
the control), and dexmedetomidine (3 × 10-7 M) 
enhanced phenylephrine (10-8 M)-induced eNOS 
phosphorylation (Fig. 4; P < 0.001 versus 
phenylephrine alone). Pretreatment with the alpha-2 
adrenoceptor antagonist rauwolscine (10-6 M) 
attenuated the dexmedetomidine-mediated increase 
of phenylephrine-induced eNOS phosphorylation 
(Fig. 4; P < 0.001 versus dexmedetomidine plus 
phenylephrine).  
  
 
Figure 1. Cumulative dexmedetomidine concentration-response curves for isolated endothelium-intact aortae (N = 5) precontracted with 10-6 M phenylephrine; 
endothelium-denuded aorta (N = 5) pretreated with Nω-nitro-L-arginine methyl ester (L-NAME, 10-4 M) and precontracted with 10-7 M phenylephrine; or 
endothelium-intact aorta (N = 7) pretreated with L-NAME (10-4 M) and precontracted with 10-6 M phenylephrine. The data are shown as the mean ± SD and 
expressed as the percentage of maximal contraction induced by phenylephrine. N indicates the number of rats from which descending thoracic aortic rings were 
derived or the number of isolated rat aortae. *P < 0.05, #P < 0.01 and †P < 0.001 versus endothelium-intact and endothelium-denuded aortae treated with L-NAME. 
‡P < 0.05, ††P < 0.01 and §P < 0.001 versus dexmedetomidine (10-9 M) in each group. 
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Figure 2. Effect of combined treatment with either dexmedetomidine (DMT, 3 × 10-7 or 10-6 M; N = 6) and phenoxybenzamine (PBZ) or phentolamine (N = 6) and 
PBZ, or treatment with PBZ alone (N = 8) on phenylephrine-induced concentration-response curves in isolated endothelium-denuded aortae pretreated with 
Nω-nitro-L-arginine methyl ester (10-4 M). The isolated endothelium-denuded rat aortae were pretreated with DMT or phentolamine, followed by post-treatment 
with PBZ. Control rings were treated with PBZ alone. Then, all of the aortic rings pretreated with PBZ, DMT and phenoxybenzamine were washed out with fresh 
Krebs solution. After baseline resting tension had recovered, phenylephrine concentration-response curves were obtained. The data are shown as the mean ± SD and 
expressed as the percentage of maximal contraction induced by isotonic 60 mM KCl. N indicates the number of rats from which descending thoracic aortic rings were 
derived. *P < 0.001 versus PBZ alone. †P < 0.05, ‡P < 0.01 and #P < 0.001 versus DMT (3 × 10-7 M) + PBZ (5 × 10-8 M). §P < 0.001 versus DMT (10-6 M) + PBZ (5 × 
10-8 M). 
 
Figure 3. A: Cumulative dexmedetomidine (DMT) concentration-response curves (N = 8) for Nω-nitro-L-arginine methyl ester (L-NAME, 10-4 M)-pretreated 
endothelium-denuded rat aortae precontracted with phenylephrine (10-7 M) or 5-hydroxytryptamine (3 × 10-6 M). The data are shown as the mean ± SD and are 
expressed as the percentage of maximal contraction induced by phenylephrine or 5-hydroxytryptamine. N indicates the number of descending thoracic aortic rings. 
*P < 0.001 versus 5-hydroxytryptamine. B: Cumulative prazosin concentration-response curves (N = 7) for L-NAME (10-4 M)-pretreated endothelium-denuded rat 
aortae precontracted with DMT (10-6 M). The data are shown as the mean ± SD and are expressed as the percentage of maximal contraction induced by DMT. N 
indicates the number of descending thoracic aortic rings. *P < 0.001 versus DMT (10-6 M).  
 
Discussion 
 This is the first study to provide laboratory 
evidence that dexmedetomidine attenuates alpha-1 
adrenoceptor-mediated phenylephrine-induced 
contraction via blockade of the alpha-1 adrenoceptor. 
Previous studies have shown that fentanyl attenuates 
alpha-1 adrenoceptor-mediated phenylephrine- 
induced vasoconstriction [16,17]. Additionally, 
dexmedetomidine has been shown to inhibit 
phenylephrine-induced contraction in the internal 
mammary and gastroepiploic arteries, suggesting that 
dexmedetomidine may have an intrinsic affinity for 
the alpha-1 adrenoceptor [7,8]. Combined treatment 
with the reversible alpha-1 adrenoceptor antagonist 
phentolamine and, subsequently, the irreversible 
alpha-1 adrenoceptor antagonist phenoxybenzamine 
enhanced phenylephrine-induced contraction 
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compared with pretreatment with 
phenoxybenzamine alone (Fig. 2), suggesting that the 
reversible occupation of alpha-1 adrenoceptors in 
vascular smooth muscle by phentolamine appears to 
spare them from irreversible blockade by 
phenoxybenzamine, which contributes to enhanced 
phenylephrine-induced contraction after washout of 
all of the pretreatment drugs (phenylephrine, 
dexmedetomidine and phenoxybenzamine) with 
Krebs solution. In addition, the supraclinical dose 
(10-7 to 10-6 M) of dexmedetomidine used in the 
current study, which exceeds the clinically relevant 
concentration (8 × 10-9 M) of dexmedetomidine for 
sedation, attenuated alpha-1 adrenoceptor-mediated 
phenylephrine-induced contraction [18]. Combined 
pretreatment with dexmedetomidine and 
phenoxybenzamine enhanced phenylephrine-induced 
contraction compared with phenoxybenzamine alone 
(Fig. 2). Taken together, these results suggest that the 
reversible occupation of alpha-1 adrenoceptors by 
dexmedetomidine may provide them with partial 
protection form irreversible blockade by 
phenoxybenzamine in a dose-dependent manner. The 
decreasing order of the magnitude of the reversible 
blockade of alpha-1 adrenoceptors observed in the 
current study was as follows: phentolamine, 10-6 M 
dexmedetomidine, 3 × 10-7 M dexmedetomidine. 
Furthermore, dexmedetomidine attenuated 
phenylephrine-induced contraction, whereas it did 
not significantly alter contraction induced by the 
5-hyroxytryptamine receptor agonist 5-hydroxy-
tryptamine, suggesting that dexmedetomidine- 
mediated inhibition appears to be associated with 
alpha-1 adrenoceptor blockade. In addition, 
dexmedetomidine-induced contraction is mediated 
by the alpha-2B and alpha-1 adrenoceptors in 
mesenteric arteries [19]. In agreement with a previous 
report, high-dose dexmedetomidine-induced 
contraction was attenuated by prazosin at a 
concentration of 3 x 10-9 M, which corresponds to the 
concentration of prazosin necessary to inhibit alpha-1 
adrenoceptors [16,19]. Dexmedetomidine shows a low 
affinity for the alpha-1 adrenoceptor and is a partial 
agonist of the human alpha-1B adrenoceptor [9,10]. 
Taking previous findings into consideration, the 
putative mechanism associated with the 
dexmedetomidine-mediated inhibition of 
phenylephrine-induced contraction is as follows 
[9,10]. Although dexmedetomidine is a highly 
selective alpha-2 adrenoceptor agonist (α2/α1 
selectivity ratio: 1620) compared with other alpha-2 
adrenoceptor agonists, at high doses, 
dexmedetomidine may occupy a small proportion of 
alpha-1 adrenoceptors [2]. Thus, because of the 
competitive inhibition of alpha-1 adrenoceptors by 
phenylephrine and high-dose dexmedetomidine, the 
number of unoccupied alpha-1 adrenoceptors 
available for phenylephrine binding may decrease, 
leading to dexmedetomidine-mediated inhibition of 
phenylephrine-induced contraction.  
 
 
 
Figure 4. Effect of dexmedetomidine alone (N = 3) or combined treatment (N = 3) with rauwolscine and dexmedetomidine on phenylephrine-induced endothelial 
nitric oxide synthase (eNOS) phosphorylation at Ser1177 in human umbilical vein endothelial cells (HUVECs). HUVECs were treated with phenylephrine (10-8 M) alone 
for 1 min; or pretreated with dexmedetomidine (3 × 10-7 M) for 10 min, followed by treatment with 10-8 M phenylephrine for 1 min; or pretreated with 10-6 M 
rauwolscine for 1 h, followed by post-treatment with dexmedetomidine (3 × 10-7 M) for 10 min and subsequent treatment with 10-8 M phenylephrine for 1 min. The 
phosphorylation of eNOS was investigated as described in the Methods. The data are shown as the mean ± SD. N indicates the number of independent experiments. 
*P < 0.001 versus the control. †P < 0.001 versus phenylephrine alone. #P < 0.001 versus dexmedetomidine plus phenylephrine. p-eNOS: phosphorylated eNOS. 
t-eNOS: total eNOS. 
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Dexmedetomidine-induced contraction is 
attenuated by endothelial nitric oxide [11,20]. Similar 
to previous reports, the magnitude of the 
dexmedetomidine-mediated attenuation of 
phenylephrine-induced contraction was higher in 
endothelium-intact aortae than in endothelium- 
denuded aortae or endothelium-intact aortae 
pretreated with L-NAME (Fig. 1). However, the 
dexmedetomidine-mediated inhibition of 
phenylephrine-induced contraction was not 
significantly altered in endothelium-denuded aortae 
or endothelium-intact aortae pretreated with 
L-NAME (Fig. 1). These results suggest that the 
dexmedetomidine-mediated attenuation of 
phenylephrine-induced contraction is partially 
mediated by endothelial nitric oxide. In agreement 
with this finding from tension analysis, further 
experiments showed that rauwolscine attenuated the 
dexmedetomidine-mediated enhancement of 
phenylephrine-induced eNOS phosphorylation, 
suggesting that dexmedetomidine-induced alpha-2 
adrenoceptor-mediated nitric oxide attenuates 
phenylephrine-induced contraction. 
Based on these results, when hypotension 
induced by high-dose dexmedetomidine infusion is 
encountered, inotropic agents and drugs inhibiting 
nitric oxide synthesis should be more effective for 
treating hypotension than alpha-1 adrenoceptor 
agonists. In the present study, we used isolated the rat 
aorta, which is regarded as a conduit vessel, whereas 
the total peripheral vascular resistance associated 
with blood pressure is determined mainly by small 
resistance arterioles, such as the mesenteric arteries. 
Even with this limitation, the 
dexmedetomidine-mediated inhibition of 
phenylephrine-induced contraction observed in the 
current study may contribute to an increased 
requirement for phenylephrine to treat hypotension 
induced by dexmedetomidine infusion for sedation 
and enhanced analgesia [4-6].  
In conclusion, our results suggest that 
dexmedetomidine attenuates phenylephrine-induced 
contraction via both alpha-1 adrenoceptor blockade in 
vascular smooth muscle and enhanced endothelial 
nitric oxide release in the isolated rat aorta.  
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